Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 9Urinary Bladder Neoplasms 4Urethral Neoplasms 4Melanoma 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Carcinoma, Hepatocellular 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Penile Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Lung Neoplasms 2HIV Infections 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

cixutumumab 2cabozantinib 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Mitotane 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Cisplatin 2tipifarnib 1sodium thiosulfate 1gossypol acetic acid 1entinostat 1cemiplimab 1Vincristine 1Tamoxifen 1Ritonavir 1Oxaliplatin 1Nivolumab 1Microscopy, Electron 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Floxuridine 1Etoposide 1Dichlorodiphenyldichloroethane 1Dexamethasone 1Cytoreduction Surgical Procedures 1CYT-6091 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Adrenocortical Carcinoma × cabozantinib × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT06900595 2026-05-22

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
48 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡